Following a full submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2011. Refer to TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|
Medicine details |
|
| Medicine name | bortezomib (Velcade®) |
| Formulation | 3.5 mg powder for solution for injection |
| Reference number | 66 |
| Indication | In combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | Full |
| Status | Superseded |
| Advice number | 0510 |
| NMG meeting date | 17/03/2010 |
| AWMSG meeting date | 28/04/2010 |
| Ratification by Welsh Government | 28/05/2010 |
| Date of issue | 01/06/2010 |
| NICE guidance | TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |